Table 4:
Adjusted variables in the studies that investigate the effect of influenza vaccine on the risk of all-cause mortality
| First author (Reference number) | Year | Adjusted variables |
|---|---|---|
| Govaert (29) | 1994 | Age, gender, previous influenza vaccination, health status |
| FLUVACS (30) | 2004 | Age, sex, anterior infarction, stemi, hypertension, diabetes |
| FLUCAD (31) | 2008 | Age, gender, weight, height, residence, employment status, hypertension, diabetes, smoking, total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides, creatinine, clinical history, actual treatment, inflammatory markers and infectious burden |
| IVCAD (33) | 2009 | Age, sex, previous influenza vaccination, hypertension, diabetes, smoking |
| De villiers (32) | 2009 | Fever ≥37 degrees, cough, sore throat, age, sex, runny nose, stuffy nose, headache |
| Phrommintikul(34) | 2011 | Age, sex, serum creatinine, treatment with angiotensin-converting enzyme inhibitors and coronary arteries |
| Verhees (37) | 2019 | Gender, age, smoking status, lung disease, heart disease, diabetes mellitus, and previous vaccinations |
| Fröbert (35) | 2021 | Age, gender, st-segment–elevation myocardial infarction, non–st-segment–elevation myocardial infarction, stable coronary artery disease, body mass index, diabetes, smoking, hyperlipidemia, hypertension, previous myocardial infarction, previous percutaneous coronary intervention, previous coronary artery bypass graft, killip class, number of diseased vessels |
| Langley (36) | 2011 | - |
| Loeb (28) | 2022 | - |